Gubra

The unique rapid response of c-Fos to activating signals makes it an excellent marker of cell activation within the #CNS. Interested in learning more about how c-Fos imaging provides insights into brain activity and function? Explore our latest blog post: https://lnkd.in/duiiNAb3 #TheGubraBlog #CNS #3DImaging

Human genetic data suggest a connection between both PICK1 and DLG4 (PSD-95) and #obesity. In series of preclinical studies recently published in Science Advances, researchers at Københavns Universitet - University of Copenhagen and Gubra report that the weight-lowering benefits of PICK1 and PSD95 inhibitors are governed by highly distinct modes of action. Using whole-brain 3D light sheet imaging of c-Fos expression, we demonstrate that pharmacological PICK1, but not PSD95, inhibition leads to recruitment of canonical brain regions involved in appetite regulation. Read more in the paper here.

Meet Martin Kræmer, senior scientist and newly appointed Department Manager of Chemistry & Bioanalysis here at Gubra. Martin is a unique mixture of a natural leader and an experimentalist, a very suitable fit for that exact role here at Gubra. The ability to play and come up with new ideas is an amazing skill. The magic happens when you gather your colleagues and co-creation begins. Congratulations on your new role Martin. Never stop experimenting!

The rise of peptide therapeutics has reshaped the pharmaceutical landscape, as exemplified by the expanding number of human peptide hormone analogues engineered to have extended circulating half-life. What does that mean for target/drug discovery and how can Gubra’s AI-assisted discovery platform streaMLine significantly accelerate hit-to-lead optimization of peptide drug candidates? Find out in our latest blog post: https://lnkd.in/dsNq5Gdg #TheGubraBlog #PeptideThearapeutics

At Gubra, we constantly pursue novel approaches to advance the design and development of therapeutic peptide drugs. We have streamlined our peptide drug discovery pipeline using machine learning-guided optimization combined with screening of large peptide libraries which have significantly expanded our pipeline of weight loss drug candidates. Today, we report the inner workings of our #streaMLine drug discovery platform in the Journal of Medicinal Chemistry. In this paper, we demonstrate how streaMLine enabled development of novel GLP-1 receptor agonist based on the backbone of secretin. Using a systematic approach combined with explainable AI, we turned secretin into a potent GLP-1R agonist while preserving beneficial the peptide stability properties of secretin. Read the paper now in JMC: https://lnkd.in/dy6Qfwxs

We’ve hit 15,000 followers! A heartfelt thank you to our community of dedicated scientists for supporting our growth. We’re excited to continue sharing news and our progress in preclinical research and to spotlight all the hardworking Gubbies as we continue our journey toward innovation in science.

We’re very excited to share the news that one of our collaboration projects with Boehringer Ingelheim (BI 3034701) has advanced into the clinic. This long-acting triple agonist peptide has the potential to become a next-generation and first-in-class obesity treatment. Read more in our press release here: https://lnkd.in/dB-MwDVa   #DrugDevelopment #Phase1Trial #Milestone 

Regular fasting periods promotes insulin and leptin surges that stimulate adipose tissue browning, a process that has gained broad attention as a potential treatment for #obesity. This study is now published in Cell Reports (Cell Press) by the Rajat Singh lab from UCLA and Albert Einstein College of Medicine. Gubra contributed 3D light sheet fluorescence microscopy imaging data on adipose tissue remodelling, indicating that intermittent feeding reduces adipocyte mean size while increasing vascular and nerve density. Download and read the full study below.

Catch us at #ADA84 in Orlando! The conference is brimming with knowledge, and we're thrilled to discuss our preclinical expertise in obesity research at booth #729. Our team has been engaged in conversations about the trends and insights in this rapidly evolving field all weekend, and we've presented two talks: ▪ ‘Renal cell-type associated therapeutic effects of semaglutide in a mouse model of hypertension-accelerated diabetic kidney disease’ ▪ ‘Semaglutide exerts anti-tumor action in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC’ The 84th Scientific Session isn’t over yet, and we have an exciting poster presentation today. Marco Tozzi will delve into ‘Metabolic Effects of Semaglutide and Resmetirom at Thermoneutrality in the Diet-Induced Obese Mouse’ (1642-P) at 12:30. Join us for a chat! Download the posters here: https://lnkd.in/dgjSuxnH Marco Tozzi, Michael Christensen, Henrik Björk Hansen, Nina Sonne, Barbora Krajníková

Gubra is moving fast! We participated in several conferences this month to connect with other industry leaders, including #Bio 2024, #EASL Congress, #Gordon Research Conference and #ECM Pharmacology.   We'll also be present at the #ADA2024 conference in Orlando this week, as well as the Global #MASLD Congress and the #FENS European Neuroscience Forum next week.   Connect with our delegation if you'd like to arrange a meeting or visit our booth to explore our models and capabilities in preclinical research:   - ADA : Marco Tozzi and Henrik Björk Hansen - MASLD Congress : Michael Feigh - FENS Forum : Jacob Hecksher-Sørensen